Bausch Health Companies Inc. has delivered a strong second quarter, surpassing earnings expectations and raising its full-year guidance.
In its latest earnings report, Bausch Health Companies Inc. (BHC.TO) posted adjusted earnings per share (EPS) of $1.26, significantly exceeding analysts' expectations of $1.01, marking a robust surprise of 24.75%. The company reported revenues of $2.85 billion, up 13% year-over-year, driven primarily by growth in its Salix and Solta Medical segments.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.45B
52W high
$11.97
52W low
$6.10
1W change
+34.24%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 16.9% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-16.9% Upside
Current Price
C$8.43
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
86.0%
Annualized
90-Day Vol
59.3%
Annualized
Trend (90d)
+38.0%
Annualized drift
90d Mean
C$9.66
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.82 | C$6.55 – C$11.87 |
| 60 trading days | C$9.23 | C$6.07 – C$14.04 |
| 90 trading days | C$9.66 | C$5.77 – C$16.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 7 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-07-29 | 1.2600 | 1.0100 | +24.8% |
| 2026-03-31 | 2026-04-29 | 0.7800 | 0.6900 | +13.0% |
| 2025-12-31 | 2026-02-18 | 1.1000 | 1.2100 | -9.1% |
| 2025-09-30 | 2025-10-29 | 1.1600 | 1.0600 | +9.4% |
| 2025-06-30 | 2025-07-30 | 0.9100 | 0.9400 | -3.2% |
| 2025-03-31 | 2025-04-30 | 0.6100 | 0.8500 | -28.2% |
Advertisement
Investor takeaway: For Canadian investors, Bausch Health's impressive earnings performance illustrates its resilience in the pharmaceutical sector despite ongoing market challenges. The company's raised guidance for 2026 further signals confidence in its growth trajectory, although analysts remain cautious about its overall market performance.
Bausch Health Reports Q2 EPS of $1.26, Beating Estimates by 24.75%
The company's revenue of $2.85 billion outperformed consensus estimates by 7.62%, showcasing its ability to drive growth amidst a challenging market environment.
Bull case
Bausch Health's strong quarterly results show solid operational performance, especially in its Salix and Solta segments. The company has consistently exceeded revenue expectations, and its raised guidance suggests it has more growth potential ahead. With a diverse product portfolio and ongoing investments in its pipeline, Bausch is well-positioned for long-term success.
Bear case
Despite the positive earnings report, Bausch Health's stock has lagged behind the market year-to-date, raising concerns about its future performance. Analysts have issued a bearish consensus rating, reflecting caution regarding the company's market positioning and competitive pressures within the pharmaceutical industry.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
